剂量学、放射生物学与合成致死:α粒子发射体放射性药物治疗
本文综述α粒子发射体放射性药物治疗的放射生物学特点、剂量学考量及合成致死策略。α粒子主要导致复杂DNA双链断裂,可联合DNA双链断裂修复抑制剂增强细胞杀伤或筛选高应答患者;其短射程高 potency 需特殊剂量学考量,包括新体模与剂量学量、从核医学影像获取微尺度药代动力学信息的形式化方法。
要点
- α粒子主要导致复杂DNA双链断裂,为联合DNA双链断裂修复抑制剂增强细胞杀伤提供机会。
- α粒子短射程高 potency 需特殊剂量学考量,涉及更新体模与相关剂量学量。
- 需进一步发展α粒子特异性成像与剂量学方法并标准化,且需严格证据表明αRPT剂量学改善患者照护。
核心结论
- α粒子发射体放射性药物治疗是正在被重新审视的令人兴奋的癌症治疗模式。
研究设计与样本
- 综述,回顾α粒子发射体放射性药物治疗的剂量学、放射生物学与合成致死相关文献。
主要发现
- α粒子导致复杂DNA双链断裂占优势,提供利用DNA双链断裂修复抑制剂增强细胞杀伤或识别α粒子RPT高应答患者的机会。
- α粒子的短射程和高 potency 需要特殊剂量学考量,本文结合近期体模更新及相关剂量学量进行综述。
- 本文提出了从患者核医学影像获取必要微尺度药代动力学信息的形式化方法。
局限性
- 原文指出需进一步发展α粒子发射体特异性成像与剂量学方法并标准化。
- 原文指出需严格证据表明应用于αRPT的剂量学改善患者照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As a treatment modality that is fundamentally different from other therapies against cancer, radiopharmaceutical therapy with alpha-particle emitters has drawn the attention of the therapy community and also the biopharmaceutical industry. Alpha-particles cause a preponderance of complex DNA double-strand breaks (DSBs). This provides an opportunity to either enhance cell kill by using DNA DSB repair inhibitors or identify patients who are likely to be high responders to alpha-emitter RPT. The short-range and high potency of alpha-particles requires special dosimetry considerations. These are reviewed in light of recent updates to the phantoms and associated dosimetric quantities used for dosimetry calculations. A formalism for obtaining the necessary microscale pharmacokinetic information from patient nuclear medicine imaging is presented. Alpha-emitter based radiopharmaceutical therapy is an exciting cancer therapy modality that is being revisited. Further development of imaging and dosimetric methods specific to alpha-particle emitters, coupled with standardization of the methods and rigorous evidence that dosimetry applied to alphaRPT improves patient care are needed moving forward.
引用
- Sgouros G. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Semin Nucl Med. 2020. PMID: 32172797. doi:10.1053/j.semnuclmed.2019.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。